The levels of BDNF (F(1, 8) = 5.661, p < 0.05; METTL3 knockout status × AP treatment, F(1, 8) = 6.013, p < 0.05) and p-TrkB/TrkB (F(1, 8) = 5.401, p < 0.05; METTL3 knockout status × AP treatment, F(1, 8) = 5.637, p < 0.05) were significantly lower in the AD+AP KO group compared to the AD +AP WT group (p < 0.05), no significant difference between the AD+AP KO group and the AD KO group (Figure 6C). This evidence concerns the gene BDNF and Alzheimer disease.